Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer
A Phase II Study of Volrustomig, Paclitaxel, and Carboplatin Followed by Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer
University of Chicago
38 participants
Oct 7, 2025
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to assess the objective response rate following neoadjuvant therapy with volrustomig, paclitaxel, and carboplatin in previously untreated human papillomavirus (HPV)-negative locally advanced head and neck squamous cell carcinoma .
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
500mg or 750mg (cycles 1-2) and 250mg thereafter IV day 1.
100mg/m2 IV day 1 and day 8.
AUC 5 IV day 1
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07065630